The Gyrolab delivers exceptional data quality. Because it’s fully automated, there’s no plate heterogeneity — just highly precise, reproducible results across runs and even across instruments. "

Gyrolab® systems are a valuable asset to Charles River for the development, validation and execution of biomarker, pharmacokinetic and immunogenicity assays for drug development.”

Gyrolab removes the expensive, time-consuming roadblocks typically associated with processing low-volume samples by significantly reducing sample and reagent consumption. The platform automates assay workflows yielding rapid, accurate results for timely and effective decision-making.”

Using Gyrolab® methods to support clinical and nonclinical studies has many benefits for our Global Bioanalytical Teams. The Gyrolab workstations improve the efficiency of our analysts in the lab and they help to keep us on the cutting edge of drug development techniques and ahead of the competition.”

These possibilities given by the Gyrolab® platform allows us as Science CRO to provide even better support and scientific advice to the clients.”

Gyrolab® platform is a choice for Agilex and our clients when high throughput is warranted...[or] reagent volume is of concern...in discovery/pre-clinical mouse models or rare matrices such as cerebral spinal fluid or ocular fluid”

Frontage believes that automation will increasingly be relied upon in the lab, replacing key repetitive manual tasks such as pipetting or plate handling, for reduced error and improved efficiency. Gyrolab® platform has delivered in-lab automation. We find that the key advantages of the Gyrolab platform are that it is automated, offers the ability for high throughput samples analysis, shortens run time, and saves precious sample volumes from Sponsors” 

Gyrolab® presents a robust platform for studies that require high throughput, have low sample volume, or have challenging analytes and matrices that are not easily analyzed with a traditional ELISA.”

Gyrolab has transformed the way we run immunoassays by dramatically reducing sample consumption, hands-on time, and overall method development timelines. The platform consistently delivers the sensitivity and robustness we need to support complex drug development programs.”

Quantification of HCP was simplified: easy to use instrument and robust data analysis with the 3D column profile.

The Gyrolab platform has been instrumental in allowing for quick turnaround of results for a number of analytical methods. The platform has high-throughput and allows for analysis of titers and residual process impurities much more efficiently, compared to traditional methods such as ELISA.

The Gyrolab system improves assay consistency and throughput for therapeutic research compared to plate-based ELISA.

Gyrolab has transformed the way we approach immunoassay development and validation. With its automation, sensitivity, and efficiency, we can minimize sample burden while maximizing data quality.”